Personalized medicine is also advancing thanks to advances in in vitro diagnostics technology.

“Additive manufacturing has made its way into our healthcare system,” says Mark Wehde of Mayo Clinic Division of Engineering.

Wearable technologies could help address some of our greatest healthcare unmet needs, says Maria Shepherd of Medi-Vantage.

“2019 was really the year of connected care/digital health—and there’s so much more to come,” says Ralph Hugeneck, senior director of technology at Nypro a Jabil Company.

One of the biggest deals in diagnostics this year could be in the process of unfolding, according to a report from Bloomberg.

A common cardiac blood test done before surgery can predict who will experience adverse outcomes after most types of surgery, said researchers from Hamilton Health Sciences.

Irvine, California-based Genomic Testing Cooperative (GTC) said recently it is collaborating with C2i Genomics to develop liquid biopsy tests for solid tumor staging and monitoring.

Illumina and Genomics England announced recently a new agreement to sequence up to 300,000 genomes over five years.

Single Technologies recently announced it has raised SEK15 million ($1.6 million) to support further development of its next-generation sequencing platform.

An assay from Roche to test immunocompromised transplant recipients for adenovirus infections has been CE marked, the company announced recently.

Personal Genome Diagnostics (PGDx) has partnered with Japan-based Eisai to develop a liquid biopsy biomarker discovery tool.

Oxford Nanopore Technologies said recently it has raised a total of ￡109.5 million ($144.4 million) between new capital investments and the sale of secondary shares.

Illumina and Pacific Biosciences announced recently after the close of the market that they have "mutually agreed" to terminate their merger agreement.

Diagnostics firm OncoCyte said recently that it has entered into definitive agreements with Pura Vida Investments, a healthcare focused registered investment advisor, and one other unnamed institutional investor......

DiaSorin Molecular has received US Food and Drug Administration clearance for its Simplexa VZV Swab Direct assay to detect varicella-zoster virus (VZV) DNA from cutaneous and mucocutaneous swab specimens, the firm announced recently.